Extending the time at each dose from 4 weeks to 6-8 weeks gives your body more time to adjust
Competing interests The authors report that there are no competing interests to declare
Before starting GLP-1 therapy, a healthcare provider will review your medical history, current medications, and overall health to ensure the treatment is safe and suitable for you
Let's embark on this transformative journey together.
4.4 Long-term safety and off-target effects Emerging reports link GLP-1RAs to rare ocular adverse events, including NAION ( 5 Conclusion In conclusion, the expanding body of evidence supports that GLP-1RAs offer a multifaceted approach to ocular therapeutics by targeting key molecular pathways involved in retinal neuroprotection, mitochondrial regulation, inflammation, vascular remodeling, and angiogenesis
These medications work by regulating appetite, slowing gastric emptying, and enhancing insulin secretion